Sheela Ann Abraham

List of Publications by Year
in descending order

26	1,638	567281 15	713466 21
papers	citations	h-index	g-index

28	28	28	2611
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Liposomal Formulation of Doxorubicin. Methods in Enzymology, 2005, 391, 71-97.	1.0	332
2	Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature, 2016, 534, 341-346.	27.8	204
3	In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magnetic Resonance in Medicine, 2004, 51, 1153-1162.	3.0	176
4	Formation of transition metalâ€“doxorubicin complexes inside liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1565, 41-54.	2.6	150
5	Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magnetic Resonance in Medicine, 2006, 56, 1011-1018.	3.0	119
6	Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. Journal of Controlled Release, 2005, 104, 271-288.	9.9	108
7	In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading. Clinical Cancer Research, 2004, 10, 728-738.	7.0	95
8	An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. Journal of Controlled Release, 2004, 96, 449-461.	9.9	94
9	CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 2016, 128, 371-383.	1.4	61
10	Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1561, 188-201.	2.6	60
11	Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. Journal of Clinical Investigation, 2014, 124, 3847-3862.	8.2	53
12	BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 2021, 12, 241.	12.8	43
13	hsa-mir183/EGR1â€“mediated regulation of E2F1 is required for CML stem/progenitor cell survival. Blood, 2018, 131, 1532-1544.	1.4	40
14	Hurdles Toward a Cure for CML: The CML Stem Cell. Hematology/Oncology Clinics of North America, 2011, 25, 951-966.	2.2	23
15	A pathway from leukemogenic oncogenes and stem cell chemokines to RNA processing via THOC5. Leukemia, 2013, 27, 932-940.	7.2	23
16	A Specific PTPRC/CD45 Phosphorylation Event Governed by Stem Cell Chemokine CXCL12 Regulates Primitive Hematopoietic Cell Motility. Molecular and Cellular Proteomics, 2013, 12, 3319-3329.	3.8	18
17	Redirecting traffic using the XPO1 police. Blood, 2013, 122, 2926-2928.	1.4	13
18	Blood extracellular vesicles from healthy individuals regulate hematopoietic stem cells as humans age. Aging Cell, 2020, 19, e13245.	6.7	12

#	Article	IF	Citations
19	Quantitative proteomics analysis of <scp>BMS</scp>â€214662 effects on <scp>CD</scp>34 positive cells from chronic myeloid leukaemia patients. Proteomics, 2013, 13, 153-168.	2.2	6
20	Extracellular vesicles tell all: How vesicle-mediated cellular communication shapes hematopoietic stem cell biology with increasing age. Experimental Hematology, 2021, 101-102, 7-15.	0.4	5
21	Biological Analysis of Human CML Stem Cells; Xenograft Model of Chronic Phase Human Chronic Myeloid Leukemia. Methods in Molecular Biology, 2016, 1465, 175-185.	0.9	2
22	Casting a NETwork instead of shooting magic bullets. Cell Cycle, 2016, 15, 3147-3148.	2.6	0
23	p53 and c-Myc Are Critical Signaling Hubs That Maintain Chronic Myeloid Leukemia. Blood, 2013, 122, 1465-1465.	1.4	0
24	Validating a network hub in leukaemia stem cells. Oncoscience, 2017, 4, 3-4.	2.2	0
25	3102 â€“ A SYNTHETIC LETHALITY APPROACH TO ERADICATE AML VIA SYNERGISTIC ACTIVATION OF PRO-APOPTOTIC P53 BY MDM2 AND BET INHIBITORS. Experimental Hematology, 2020, 88, S70.	0.4	0
26	A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors. Blood, 2020, 136, 14-14.	1.4	0